Recombinant vector for biosynthesis of indolepropionic acid, engineering bacterium and application thereof
By constructing and expressing recombinant vectors in E.coli BL21 (DE3), the complexity and low yield of indole propionic acid chemical synthesis method were solved, and efficient and low-cost biosynthesis of indole propionic acid was achieved. The output has increased by 52 times and has broad application prospects.
Patent Information
- Application Number
- CN202411248087.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-12
AI Technical Summary
In the prior art, the chemical synthesis method of indole propionic acid is complicated, the cost is high, the yield is low, and the environmental pollution is severe. It is difficult to achieve large-scale synthesis by microbial fermentation method. It is necessary to develop a simple, low-cost and stable production of indole propionic acid. Acid method.
A recombinant vector was constructed, including the anthoaminobenzoate synthase gene trpED, the fused indole-3-glycerol phosphate synthase/phosphorose anthoaminobenzoate isomerase gene trpC and tryptophan synthase gene trpBA and benzene The acyl-CoA dehydrase subunit fldC gene was transformed into E.coli BL21 (DE3), and an engineered bacteria that can stably synthesize indole propionic acid was constructed.
It is achieved that the intracellular L-tryptophan is stable to convert indolypropionic acid without the need for exogenous addition of L-tryptophan, which has increased the yield by 52 times, with low cost and high control, and avoids industrial Large-scale extraction, separation and purification process is environmentally friendly and has good industrial application prospects.
Smart Images

Figure CN118931933A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of bioengineering, and specifically relates to a recombinant vector, an engineering bacterium and an application thereof for biosynthesis of indolepropionic acid. Background Art
[0002] Indole propionic acid (IPA), also known as indole-3-pyruvic acid (IPA), is a tryptophan deamination product derived from intestinal microorganisms, which has intracellular signaling activity. IPA has the functions of maintaining intestinal integrity, improving intestinal barrier function, regulating immunity and reducing inflammatory response. In addition, IPA can be used as a plant growth stimulant and pharmaceutical intermediate. IPA has auxin biological activity and can be absorbed by the roots, stems, leaves and flowers of plants to promote rooting and fruit setting. It is expected to be developed and applied as a new green feed additive.
[0003] At present, the synthesis methods of IPA mainly include chemical synthesis and microbial fermentation. There are three main ways to chemically synthesize IPA: (1) chemical synthesis of IPA using diethyl adipate as raw material. This method has a long synthesis path, cumbersome operation, and low yield of only 12.9%; (2) chemical synthesis of IPA using indole and acrylic acid as raw materials. This method is relatively mature. After two steps, IPA is synthesized with a yield of 57.1%-78.3%, but the preparation of the reagent Meldrum acid required for the reaction is very difficult and difficult to put into practical application; (3) chemical synthesis of IPA using indole, isoxazole and aromatic aldehyde as raw materials. This method can synthesize IPA from cheap materials with a high yield of 79%, but this method has certain by-products, and the separation and purification is complicated and costly. Therefore, the chemical synthesis method has complex steps, high cost, low yield, and serious environmental pollution, which is not suitable for large-scale production. It is necessary to develop a microbial fermentation method to produce IPA.
[0004] In humans and animals, IPA is entirely produced by the metabolism of tryptophan by intestinal bacteria. Tryptophan is one of the essential amino acids, which is mainly obtained from food, and a small part is synthesized by intestinal bacteria. It is reported that 2% to 4% of tryptophan is metabolized by intestinal bacteria to produce tryptamine, indole and various indole derivatives. Intestinal bacteria with different tryptophan metabolizing enzymes can break down tryptophan into different types of metabolites, and there are huge differences in the metabolic capabilities of different bacteria. Studies have shown that bacteria that can independently complete tryptophan metabolism and produce IPA mainly come from Clostridium and Peptostreptococcus, including C.sporogenes, C.botulinum and Peptostreptococcus anaerobius. They mainly convert tryptophan into indole-3-pyruvic acid (IPyA) by aromatic amino acid aminotransferase (ArAT), and IPyA is then catalyzed by indolelactate dehydrogenase (ILDH), indolelactate dehydratase (ILD) and acyl-CoA dehydrogenase (ACD) to generate IPA. Therefore, it is necessary to develop a carrier and engineered bacteria that is simple, does not require the addition of additional catalysts, is low in cost, and can synthesize IPA in large quantities. Summary of the invention
[0005] In view of some deficiencies in the prior art, the present invention provides a recombinant vector, an engineered bacterium and an application thereof for biosynthesis of indolepropionic acid; the present invention utilizes microbial metabolic engineering and synthetic biology methods to construct a recombinant vector for synthesizing indolepropionic acid, wherein the recombinant vector comprises an anthranilate synthase gene trpED, a fused indole-3-glycerolphosphate synthase / phosphoribosylanthranilate isomerase gene trpC and a tryptophan synthase gene trpBA and a benzoyl-CoA dehydratase subunit fldC gene; the recombinant vector is transformed into E.coli BL21 (DE3) cells to achieve overexpression of the above four genes, thereby obtaining an engineered bacterium for biosynthesis of indolepropionic acid, wherein the engineered bacterium can stably synthesize a large amount of indolepropionic acid and has broad application prospects.
[0006] In order to achieve the above technical objectives, the present invention adopts the following technical means:
[0007] The present invention first provides a recombinant vector for biosynthesis of indolepropionic acid. The recombinant vector is constructed on an expression vector to express an anthranilate synthase gene trpED, a fused indole-3-glycerolphosphate synthase / phosphoribosylanthranilate isomerase gene trpC and a tryptophan synthase gene trpBA and a benzoyl-CoA dehydratase subunit gene fldC.
[0008] Preferably, the expression vector comprises vector pET-28a(+);
[0009] The nucleotide sequences of trpED, trpC, trpBA and fldC are shown in SEQ ID NOs. 1-4.
[0010] The present invention also provides an engineering bacterium, wherein the engineering bacterium comprises the above-mentioned recombinant vector.
[0011] Preferably, the host bacteria of the engineering bacteria include Escherichia coli, preferably Escherichia coli BL21 (DE3).
[0012] The present invention also provides the use of the above-mentioned recombinant vector and engineering bacteria in biosynthesis of indolepropionic acid.
[0013] Preferably, the application is: biosynthesizing indolepropionic acid using intracellularly synthesized L-tryptophan as a precursor.
[0014] The present invention also provides a method for biosynthesizing indolepropionic acid, which comprises: using the above-mentioned engineering bacteria to ferment and produce indolepropionic acid.
[0015] Preferably, the fermentation method comprises:
[0016] (1) inoculating the engineered bacteria into a fermentation medium, adding kanamycin to carry out a first shaking culture, and after the culture is completed, taking a bacterial solution with a final concentration of 1% (v / v) and inoculating it into a fermentation medium for a second shaking culture;
[0017] (2) After culturing for a period of time, isopropyl-β-D-thiogalactoside was added thereto for a third shaking culture. After the culture was completed, the culture was transferred to a fermentation tank containing glucose for fermentation. During the fermentation process, glucose was added and the bacterial liquid was sampled at regular intervals. The supernatant was obtained by centrifugation and filtered with a filter membrane to detect the production of indolepropionic acid.
[0018] Preferably, in step (1), the conditions for the first shaking culture and the second shaking culture are: culture at 37° C. and 220 rpm; and the fermentation medium is liquid LB medium.
[0019] Preferably, in step (2), the conditions for the third shaking culture are: culture at 30°C and 220 rpm;
[0020] The fermentation conditions are as follows: fermentation is carried out at a temperature of 30-37° C., a pH of 6.0-8.0, and an aeration volume of 0.1-1 vvm of air, and glucose is added during the fermentation process until the fermentation is 36-48 hours and then stopped.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] The present invention utilizes microbial metabolic engineering and synthetic biology methods to construct a new recombinant vector IPA-pET28a comprising anthranilate synthase gene trpED, fused indole-3-glycerolphosphate synthase / phosphoribosylanthranilate isomerase gene trpC and tryptophan synthase gene trpBA and benzoyl-CoA dehydratase subunit gene fldC, and transfers the recombinant vector into E.coli BL21 (DE3), constructs an engineered bacterium, and the engineered bacterium can stably convert intracellularly synthesized L-tryptophan into indolepropionic acid without exogenous addition of L-tryptophan, thereby realizing a fermentation process of biosynthesizing indolepropionic acid with bacteria independently synthesizing L-tryptophan as a substrate. Compared with exogenous addition of L-tryptophan, the method of the present invention has low cost and high controllability, and reduces the influence of exogenous L-tryptophan on bacterial production.
[0023] The engineered bacteria containing the recombinant vector of the present invention can realize the conversion of intracellularly synthesized L-tryptophan into indolepropionic acid, thereby synthesizing indolepropionic acid in large quantities and stably. The engineered bacteria are used for fermentation in a 5L fermenter. After the fermentation conditions are optimized, the recombinant Escherichia coli can produce 2.73g / L of indolepropionic acid, which has a very broad application prospect. In contrast, the method for biosynthesis of indolepropionic acid described in the prior art can only produce 52.31mg / L, and the method of the present invention increases the indolepropionic acid yield by 52 times.
[0024] The method of the present invention is based on the transformation of microorganisms and utilizes recombinant Escherichia coli strains to synthesize indolepropionic acid, thereby avoiding large-scale industrial extraction, separation, and purification processes, and does not require synthesis conditions such as high temperature and high pressure, nor does it require the use of catalysts. It is not only environmentally friendly, but also easy to control production costs, and has good industrial application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 Schematic diagram of the construction of the IPA-pET28a vector of the present invention.
[0026] Figure 2 It is the agarose gel electrophoresis diagram of the gene cloning of the present invention; in the diagram, a is trpED, b is trpC, and c is trpBA.
[0027] Figure 3This is an agarose gel electrophoresis diagram for PCR verification of the bacterial solution of the present invention; in the diagram, a is trpED, b is trpC, c is trpBA, and d is fldC.
[0028] Figure 4 This is the liquid chromatogram for detecting the production of indolepropionic acid in the fermentation broth of engineered bacteria. DETAILED DESCRIPTION
[0029] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments, but the protection scope of the present invention is not limited thereto. It will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are followed. The reagents or instruments used are not indicated by the manufacturer and are conventional products that can be purchased on the market.
[0030] The primer synthesis and sequencing used in the following examples were completed by GenScript Biotech Co., Ltd. The expression vector used was the Escherichia coli expression vector pET-28a(+) purchased from Shanghai Core Biotechnology Co., Ltd., and the Escherichia coli MG1655 used was purchased from Beina Biotechnology; the Escherichia coli BL21(DE3) was purchased from Beijing Qingke Biotechnology Co., Ltd.
[0031] The primers used in the following examples are as follows:
[0032] trpED-F: ATGCAAACAC AAAAACCGAC TC (SEQ ID NO.5);
[0033] trpED-R:TTACCCTCGTGCCGCCAGTGCG (SEQ ID NO. 6);
[0034] trpC-F: ATGATGCAAACCGTTTTAGCGA (SEQ ID NO.7);
[0035] trpC-R: TTAATATGCGCGCAGCGTCTGG (SEQ ID NO. 8);
[0036] trpBA-F: ATGACAACAT TACTTAACCC CT (SEQ ID NO. 9);
[0037] trpBA-R: TTAACTGCGCGTCGCCGCTTTC (SEQ ID NO. 10);
[0038] fldC-F: ATGAGCAACAGCGATAAATTCT (SEQ ID NO. 11);
[0039] fldC-R: TTACAAGGTTTCAGAAAAGGCC (SEQ ID NO. 12).
[0040] Example 1: Construction of recombinant vector IPA-pET28a
[0041] (1) Extraction of genomic DNA from Escherichia coli MG1655:
[0042] Collect the bacterial suspension of Escherichia coli MG1655 cultured overnight into a 1.5 mL centrifuge tube, centrifuge at 12,000 rpm for 30 seconds, remove the supernatant and fully suspend the bacteria in 500 μL lysis buffer, then add 15 μL Proteinase K, mix well and place in a constant temperature water bath at 37°C for 1 hour, add 200 uL NaCl after the water bath, mix by inversion for 30 seconds, and centrifuge at 12,000 rpm for 30 seconds after an ice bath for 10 minutes.
[0043] After centrifugation, carefully aspirate the supernatant and add 2 times the volume of anhydrous ethanol, invert and mix, centrifuge at 12,000rpm for 5min, then discard the supernatant and fully suspend the precipitate in 300μL sterile water, add 15μL RNaseA, mix, and place in a constant temperature water bath at 37℃ for 1h. After the water bath ends, add 200μL saturated phenol and 200μL tetrachloromethane, shake and mix, and centrifuge at 12,000rpm for 1min. Collect the supernatant into a 1.5mL centrifuge tube for later use.
[0044] To the collected supernatant, add 2 times the volume of anhydrous ethanol, invert and mix, centrifuge at 12,000 rpm for 2 min, discard the supernatant and add 500 μL 70% ethanol for washing, centrifuge at 12,000 rpm for 1 min, discard the ethanol, precipitate at room temperature and air-dry, obtain the genomic DNA of Escherichia coli MG1655 after drying, dissolve in 200 μL sterile water, and place at 20°C for use.
[0045] (2) Construction of recombinant vector IPA-pET28a:
[0046] Figure 1 This is a schematic diagram of the construction of the IPA-pET28a vector of the present invention. The specific construction steps are as follows:
[0047] The E. coli MG1655 genome obtained in step (1) was used as a template, and trpED-F and trpED-R were used as primers to perform PCR amplification of the gene trpED. The conditions for PCR amplification were 95°C for 3 min; 95°C for 30 s, 55°C for 30 s, 72°C for 90 s, 35 cycles; 72°C for 5 min, and the correctness of the product bands was detected by agarose gel electrophoresis (e.g. Figure 2 ), then the PCR product was recovered, and the unpurified PCR product was sequenced and compared. The comparison results showed that the trpED gene sequence obtained by PCR amplification was correct; the nucleotide sequence of the trpED was shown in SEQ ID NO.1.
[0048] The E. coli MG1655 genome obtained in step (1) was used as a template, and trpC-F and trpC-R were used as primers to perform PCR amplification of the gene trpC. The conditions for PCR amplification were 95°C for 3 min; 95°C for 30 s, 55°C for 30 s, 72°C for 1 min, 35 cycles; 72°C for 5 min, and the correctness of the product bands was detected by agarose gel electrophoresis (e.g. Figure 2 ), then the PCR product was recovered, and the unpurified PCR product was sequenced and compared. The comparison results showed that the trpC gene sequence obtained by PCR amplification was correct; the nucleotide sequence of the trpC was shown in SEQ ID NO.2.
[0049] The E. coli MG1655 genome obtained in step (1) was used as a template, and trpBA-F and trpBA-R were used as primers to perform PCR amplification of the gene trpBA. The conditions for PCR amplification were 95°C for 3 min; 95°C for 30 s, 55°C for 30 s, 72°C for 1 min, 35 cycles; 72°C for 5 min, and the correctness of the product bands was detected by agarose gel electrophoresis (e.g. Figure 2 ), then the PCR product was recovered, and the unpurified PCR product was sequenced and compared. The comparison results showed that the trpBA gene sequence obtained by PCR amplification was correct; the nucleotide sequence of the trpBA was shown in SEQ ID NO.3.
[0050] After the fldC gene codon was optimized, it was synthesized by GenScript Biotech Co., Ltd. The nucleotide sequence of the optimized fldC gene is shown in SEQ ID NO.4.
[0051] The obtained genes trpED, trpC, trpBA and fldC were sequentially constructed into the Escherichia coli expression vector pET-28a(+) by homologous recombination, and finally the recombinant vector IPA-pET28a was obtained.
[0052] Example 2: Construction of engineered bacteria
[0053] (1) Construction and verification of engineered bacteria:
[0054] Take 2 μL (100 ng / μL) of the recombinant plasmid IPA-pET28a obtained in Example 1 and add it to 100 μL of Escherichia coli BL21 (DE3) competent cells. Tap the tube wall to mix, let it stand on ice for 30 min, then heat shock it in a 42°C water bath for 90 s. Immediately cool it on ice for 3 min after the heat shock, then add it to 900 μL LB liquid culture medium and shake culture it at 37°C for 1 h. After the culture is completed, centrifuge it at 5,000 rpm (2,500 × g) for 5 min, discard 900 μL of supernatant for later use, and resuspend the cells with the remaining culture medium for later use.
[0055] Preheat the LB solid culture medium plate containing kanamycin (Kan) resistance in a 37°C incubator, and gently spread the resuspended bacteria on the Kan-resistant plate with a sterile spreading rod, and incubate inverted in a 37°C incubator for 16 hours. After the incubation, use a sterile toothpick to pick a single colony and place it in 1 mL LB liquid culture medium containing Kan antibiotics (final concentration of 50 μg / mL), and shake and culture at 37°C, 200 rpm for 5 hours until the bacterial solution becomes turbid, and then perform bacterial solution PCR verification, and verify whether the vector is successfully connected based on the electrophoresis bands and sequencing results.
[0056] Figure 3 This is the agarose gel electrophoresis diagram for verification of bacterial liquid PCR of the present invention. It can be seen from the figure that the size of the electrophoresis band is correct, proving that the vector is successfully connected.
[0057] (2) Capacity verification of engineered bacteria to produce indolepropionic acid by fermentation:
[0058] This example also verifies the ability of the above-constructed engineered bacteria to produce indolepropionic acid by fermentation. The specific verification steps are as follows:
[0059] S1. The engineered bacteria constructed above were inoculated into 5 mL of liquid LB medium, 5 μL of Kan antibiotics were added, and cultured in a shaker at 37°C 220 rpm for 12 h. Then 1% of the bacterial solution was inoculated into 50 mL of a 250 mL Erlenmeyer flask containing liquid LB, and cultured in a shaker at 37°C 220 rpm;
[0060] S2. When OD 600 =0.6, add 250 μL 0.1 mol / L isopropyl-β-D-thiogalactoside (IPTG), and continue to culture at 30°C and 220 rpm. 600=4, transferred to a 5L fermenter containing 25g / L glucose, and continued fermentation for 48h. The fermentation temperature of the 5L fermenter was 37°C, 50% ammonia water was used to adjust the fermentation pH to 6.0-7.0, the ventilation volume was 0.1-1vvm air, the rotation speed was 200-500rpm, and glucose was added during the fermentation process to control the glucose concentration in the fermentation liquid to 20-30g / L. After 36h, the addition was stopped until the fermentation was completed.
[0061] S3. After the fermentation, 1.5 mL of the fermentation broth was centrifuged at 8,500 rpm for 3 min, and the supernatant was filtered through a 0.22 μm filter membrane and transferred to a liquid phase bottle; the yield of indolepropionic acid was detected by high performance liquid chromatography (HPLC), a reversed phase C18 column and a UV Detector 279 nm, wherein the mobile phase was water and acetonitrile gradient elution, the flow rate was 1 mL / min, and the injection volume was 10 μL. The measurement results are as follows: Figure 4 shown.
[0062] Figure 4 The liquid phase chromatogram of the detection of indolepropionic acid produced by the fermentation liquid of the engineered bacteria shows that the chromatographic peak of indolepropionic acid appears at 5.00-6.00min, which indicates that the engineered bacteria constructed by the present invention can produce indolepropionic acid intracellularly without exogenous L-tryptophan. According to the peak area of the chromatographic peak of indolepropionic acid in the spectrum, the indolepropionic acid content is calculated to be 2.73g / L. In contrast, the biosynthetic indolepropionic acid yield described in the prior art is only 52.31mg / L, and the indolepropionic acid yield of the method of the present invention is increased by 52 times. This shows that the engineered strain constructed by the present invention can not only realize the conversion of intracellularly synthesized L-tryptophan into indolepropionic acid, but also has good production efficiency.
[0063] In summary, the present invention utilizes microbial metabolic engineering and synthetic biology methods to construct a recombinant vector for synthesizing indolepropionic acid, wherein the recombinant vector comprises an anthranilate synthase gene trpED, a fused indole-3-glycerolphosphate synthase / phosphoribosylanthranilate isomerase gene trpC and a tryptophan synthase gene trpBA, and a benzoyl-CoA dehydratase subunit fldC gene; the recombinant vector is transformed into E. coli BL21 (DE3) cells to achieve overexpression of the above four genes to obtain an engineered bacterium for biosynthesis of indolepropionic acid, and the engineered bacterium can stably synthesize a large amount of indolepropionic acid, and has broad application prospects.
[0064] The embodiments are preferred implementations of the present invention, but the present invention is not limited to the above-mentioned implementations. Any obvious improvements, substitutions or modifications that can be made by those skilled in the art without departing from the essential content of the present invention belong to the protection scope of the present invention.
Claims
1. A recombinant vector for biosynthesis of indolepropionic acid, characterized in that: The recombinant vector is constructed and expressed on the expression vector anthranilate synthase gene trpED, fused indole-3-glycerolphosphate synthase / phosphoribosyl anthranilate isomerase gene trpC and tryptophan synthase gene trpBA and benzoyl-CoA dehydratase subunit gene fldC.
2. The recombinant vector according to claim 1, characterized in that The expression vector includes vector pET-28a(+); The nucleotide sequences of trpED, trpC, trpBA and fldC are shown in SEQ ID NOs. 1-4.
3. An engineered bacterium, characterized in that: The engineered bacteria comprises the recombinant vector according to claim 1.
4. The engineered bacteria according to claim 3, characterized in that The host bacteria of the engineering bacteria include Escherichia coli.
5. Use of the recombinant vector according to claim 1 or the engineered bacteria according to claim 3 in the biosynthesis of indolepropionic acid.
6. The use according to claim 5, characterized in that: The application is: biosynthesizing indolepropionic acid using L-tryptophan synthesized in the cell as a precursor.
7. A method for biosynthesizing indolepropionic acid, characterized in that: The method comprises: using the engineered bacteria described in claim 3 to ferment and produce indolepropionic acid.
8. The method according to claim 7, characterized in that The fermentation method comprises: (1) inoculating the engineered bacteria into a fermentation medium, adding kanamycin to carry out a first shaking culture, and after the culture is completed, taking 1% (v / v) of the bacterial solution and inoculating it into a fermentation medium for a second shaking culture; (2) After culturing for a period of time, isopropyl-β-D-thiogalactoside was added thereto for a third shaking culture. After the culture was completed, the culture was transferred to a fermentation tank containing glucose for fermentation. During the fermentation process, glucose was added, and the bacterial liquid was sampled at regular intervals. The supernatant was obtained by centrifugation and filtered through a filter membrane to detect the production of indolepropionic acid.
9. The method according to claim 8, characterized in that In step (1), the conditions for the first shaking culture and the second shaking culture are: culture at 37° C. and 220 rpm; and the fermentation medium is liquid LB medium.
10. The method according to claim 8, characterized in that In step (2), the conditions for the third shaking culture are: culture at 30° C. and 220 rpm; The fermentation conditions are as follows: fermentation is carried out at a temperature of 30-37° C., a pH of 6.0-8.0, and an aeration volume of 0.1-1 vvm of air, and glucose is added during the fermentation process until the fermentation is 36-48 hours and then stopped.
